EU/3/02/112: Orphan designation for the treatment of hepatocellular carcinoma

Doxorubicin carbon / iron magnetically targeted microparticles

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2008 on request of the Sponsor.

On 11 September 2002, orphan designation (EU/3/02/112) was granted by the European Commission to Interface International Consultancy Limited, United Kingdom, for doxorubicin carbon/iron magnetically targeted microparticles for the treatment of hepatocellular carcinoma.

Key facts

Active substance
  • Doxorubicin carbon
  • iron magnetically targeted microparticles
Intended use
Treatment of hepatocellular carcinoma
Orphan designation status
Withdrawn
EU designation number
EU/3/02/112
Date of designation
11/09/2002
Sponsor
Interface International Consultancy Limited
Hadhams, Main Street
Huggate
York
YO42IYQ
United Kingdom
Telephone: +44 1337 288420
Telefax: +44 1337 288148
E-mail: infoatinterface@aol.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating